after gsk with all guns blazing, page-13

GSK will look first at cash assets of BTA, if BTA can sustain the cash level to drag this case for years then GSK might want to settle. BTA has a strong case and might even win this. All product dev by BTA are years away. Court cases such as this can take several years depending on how the game is played. 20 million forecast revenue for 2007 is great, if recommendation to have 50% relenza and 50% tamiflu is followed then BTA will definitely get a re-rating.